Tanezumab in Osteoarthritis of the Hip or Knee (2)

• Status: Completed
• Trial end date: 2010-08-16
• Target enrollment: 0
• Participant gender: All

Summary

Test the efficacy and safety of 2 doses of tanezumab compared with naproxen and placebo in patients with osteoarthritis

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Pfizer
• Treatments: Naproxen; Tanezumab

Criteria

Inclusion Criteria:

• Osteoarthritis of the hip or knee according to Kellgren-Lawrence x-ray grade of 2

Exclusion Criteria:

• pregnancy or intent to become pregnant

• BMI greater than 39

• other severe pain, significant cardiac, neurological or psychiatric disease